81 completed, 4 unknown, 3 recruiting, 2 terminated. 56 Phase 1, 18 Not applicable, 12 Phase 3, 4 Early Phase 1, 2 Phase 2.
Follow Test Product: new trials by email Literature Review of Test Product trials Research Report on Test Product
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years Test Product - Pain | Phase 1 | Recruiting | HALEON | 12 | 2026-06-19 | 2026-06-30 |
| A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea. Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% - Rosacea | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 865 | 2025-12-09 | 2026-08-31 |
| A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 575 | 2025-10-13 | 2026-04-22 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Quizartinib, Placebo, Chemotherapy - Leukemia | Phase 3 | Active not recruiting | Daiichi Sankyo | 700 | 2024-11-19 | 2026-07-02 |
| Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment Quizartinib - Hepatic Impairment | Phase 1 | Recruiting | Daiichi Sankyo | 12 | 2024-09-30 | 2026-04-01 |
| A Comparative Study of Cosmetic Product in Subjects With Facial Acne During an Associated-treatment Phase Followed by a Maintenance Phase Test product, Comparator product - Acne | Not applicable | Recruiting | Pierre Fabre Dermo Cosmetique | 60 | 2024-07-03 | 2024-12-04 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1000 | 2024-06-20 | 2024-12-13 |
| Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients. Test product, Control Product - Vitiligo | Terminated | Pierre Fabre Dermo Cosmetique | 19 | 2024-05-23 | 2026-05-08 | |
| A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 382 | 2024-05-13 | 2024-11-05 |
| A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Ranibizumab 10mg/ml Injection, Lucentis - Diabetic Macular Edema, Diabetic Retinopathy | Phase 3 | Completed | Incepta Pharmaceuticals Ltd | 70 | 2024-03-30 | 2026-09-25 |
| A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) Trastuzumab (proposed Trastuzumab biosimilar), Herclon - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Incepta Pharmaceuticals Ltd | 80 | 2024-01-23 | 2025-07-22 |
| A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo - Tinea Versicolor | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 430 | 2023-12-04 | 2024-03-12 |
| Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma Group TP, Group CYS - Melasma | Not applicable | Unknown | Cosmetique Active International | 140 | 2023-10-06 | 2024-02-26 |
| Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route Test Product, Reference product, Reference Medicinal Product - Rheumatoid Arthritis | Phase 1 | Unknown | Dr. Reddy's Laboratories Limited | 330 | 2023-10-03 | 2023-11-13 |
| A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis. Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo - Atopic Dermatitis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 476 | 2023-08-11 | 2024-11-05 |
| Clinical Study on Malodor test product, Control product - Oral Malodor | Phase 3 | Completed | Colgate Palmolive | 100 | 2023-06-01 | 2024-03-08 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 762 | 2023-02-22 | 2023-10-02 |
| Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule - Tooth, Impacted, Tooth Diseases | Phase 3 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 294 | 2022-08-09 | 2023-06-22 |
| Synthetic Male Condom Slippage-Breakage Study Test Product, Control Product - Contraceptive, Sexually Transmitted Diseases | Not applicable | Completed | Church & Dwight Company, Inc. | 600 | 2022-06-10 | 2023-11-08 |
Showing 20 of 92. Sign in to see all of them.
Fasting (12) · Lecithin Cholesterol Acyltransferase Deficiency (12) · Acne Vulgaris (8) · Asthma (6) · Facies (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Abdominal Pain (1) · Arthritis, Rheumatoid (1) · Autistic Disorder (1) · Breast Diseases (1) · Breast Neoplasms (1) · Constipation (1) · Dermatitis, Atopic (1) · Diabetes Mellitus (1)
IPCA Laboratories Ltd. (29) · Sun Pharmaceutical Industries, Inc. (12) · GlaxoSmithKline (6) · Actavis Inc. (5) · Daiichi Sankyo (3) · Respirent Pharmaceuticals Co Ltd. (3) · Amneal Ireland Limited (2) · Danone Asia Pacific Holdings Pte, Ltd. (2) · Incepta Pharmaceuticals Ltd (2) · Lupin Ltd. (2) · Oystershell NV (2) · Pierre Fabre Dermo Cosmetique (2) · Aurobindo Pharma Ltd (1) · Biogen (1) · Center of Food and Fermentation Technologies (1)
India (33) · United States (32) · Brazil (6) · Canada (5) · Singapore (5) · Belgium (4) · France (4) · United Kingdom (4) · China (3) · Germany (3) · Greece (3) · Australia (2) · Bangladesh (2) · Bulgaria (2) · Croatia (2)
Natalie Yantovskiy (7) · Dr. Tarang Shah, M.D. (5) · Dr. Hardik Dave, M.B.B.S (4) · Dr. Hardik Dave, M.B.B.S. (4) · Zaidoon A. Al-Zubaidy (4) · Daniel V. Freeland, DO (3) · Dr. Manish Singhal, MBBS (3) · Dr. Nirav Gandhi, M.D. (3) · Dr. Rupesh Vala, M.B.B.S. (3) · Dr. Suhas Khandave, M.D. (3) · Ioannis Stefanidis, Professor (3) · Dr. Manish Singhal, M.B.B.S (2) · Dr. Tarang Girishbhai Shah, M. D. (Pharmacology) (2)
PMID 27227384, PMID 29859851, PMID 30506361, PMID 31249709, PMID 31461548, PMID 37116523, PMID 40037774, PMID 40072601, PMID 40079105, PMID 41052406, PMID 41189742, PMID 41791832, PMID 41949390, PMID 42434847
2014 (1), 2015 (1), 2023 (1)